Collagen and heparin matrices for growth factor delivery

Journal of Controlled Release

Volumn 48, Issue 1, 1997, Pages 29-33

  Schroeder Tefft, J A ^a   Bentz, H ^a   Estridge, T D ^a  

^a ALLERGAN INC   (United States)

Author keywords

Fibrillar collagen; Heparin; Stabilization; Transforming growth factor beta 2 (TGF 2)

Indexed keywords

COLLAGEN; HEPARIN; SERUM ALBUMIN; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FORMULATION; DRUG SCREENING; PRIORITY JOURNAL;

EID: 0030873379     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00055-2     Document Type: Article

References (19)

1. D. Gospodarowicz, J. Cheng, Heparin protects basic and acidic FGF from inactivation, J. Cell. Physiol. 128 (1984) 475-484.
2. J. Murray, L. Brown, M. Klagsbrun, R. Langer, A microsustained release system for epidermal growth factor, In Vitro 19 (1983) 743-748.
3. E.R. Edelman, E. Mathiowitz, R. Langer, M. Klasburn, Controlled and modulated release of basic fibroblast growth factor, Biomaterials 12 (1991) 619-626.
4. E.B. Hunziker, R. Shaw, Method and composition for the treatment and repair of defects of lesions in cartilage, US Patent 5,206,023, Apr. 27, 1993.
5. E.B. Hunziker, R. Shaw, Method and composition for the treatment and repair of defects of lesions in cartilage or bone, US Patent 5,270,300, Dec. 14, 1993.
6. E.B. Hunziker, R. Shaw, Methods and compositions for the treatment and repair of defects of lesions in cartilage, US Patent 5,368,858, Nov. 29, 1994.
7. G. Ksander, Y. Ogawa, Collagen wound healing matrices and process for their production, US Patent 4,950,483, Aug. 21, 1990.
8. G. Chu, Y. Ogawa, J.M. McPherson, G. Ksander, B. Pratt, D. Hendricks, H. McMullin, Collagen wound healing matrices and process for their production, US Patent 5,024,841, June 18, 1991.
9. G. Chu, Y Ogawa, J.M. McPherson, G. Ksander, B. Pratt, D. Hendricks, H. McMullin, Collagen wound healing matrices and process for their production, US Patent 5,110,604, May 5, 1992.
10. J. Sundsmo, G. Ksander, J. McPherson, Wound healing composition, US Patent 4,760,131, Jul. 26, 1988.
11. J.M. McPherson, S.J. Sawamura, R.A. Condell, W. Rhee, D. Wallace, The effects of heparin on the physicochemical properties of reconstituted collagen, Collagen Rel. Res. 1 (1988) 65-82.
12. P. Bashkin, S. Doctrow, M. Klagsbrun, C. Svahn, J. Folkman, I. Vlodavsky, Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparintinase and heparin-like molecules. Biochemistry 28 (1989) 1737-1743.
13. R. Flaumenehaft, D. Moscatelli, O. Saksela, D. Rifkin, Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis, J. Cell. Physiol. 140 (1989) 75-81.
14. A.B. Roberts, M.B. Sporn, R.K. Assoian, J.M. Smith, N.S. Roche, I.M. Wakefield, U.I. Heine, L.A. Liotta, V. Falanga, J.H. Kehrle, A.S. Fauci, Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro, Proc. Natl. Acad. Sci. USA 83 (1986) 4167-4171.
15. G.A. Ksander, Y. Ogawa, G.H. Chu, H. McMullin, J.S. Rosenblatt, J.M. McPherson, Exogenous transforming growth factor-beta2 enhances connective tissue formation and wound strength in guinea pig dermal wound healing by secondary intent, Ann. Surg. 211 (1989) 288-294.
16. T.R. Knapp, E.E. Luck, J.R. Daniels, Behavior of solubilized collagen as a bioimplant, J. Surg. Res. 23 (1977) 96-105.
17. F. DeLustro, R.A. Condell, M.A. Nguyen, J.M. McPherson, A comparative study of the biological and immunological response to medical devices derived from dermal collagen, J. Biomed. Mater. Res. 20 (1986) 109-120.
18. L.R. Ellingsworth, F. DeLustro, J.E. Brennan, S. Sawamura, J.M. McPherson, The human immune response to reconstituted bovine collagen, J. Immunol. 136 (1986) 877-882.
19. T. McCaffrey, D. Falcone, C. Brayton, L. Agarwal, F. Welt, B. Weksler, Transforming growth factor-/31 is potentiated by heparin via dissociation of the transforming growth factor-β-α-2-macroglobulin inactive complex. J. Cell Biol. 109 (1992) 441-448.